everi
viru
start
life
cycl
enter
suscept
host
cell
host
celltarget
abil
viru
mainli
determin
presenc
appropri
host
cell
receptor
engag
viru
success
host
cell
entri
envelop
virus
evolv
divers
array
envelop
glycoprotein
membran
differ
receptor
associ
capabl
bestcharacter
exampl
viral
cell
receptor
relationship
might
interact
human
immunodefici
viru
hiv
glycoprotein
human
lymphocyt
molecul
due
essenti
role
overal
viru
life
cycl
viral
entri
attract
target
vaccin
antivir
drug
develop
goal
disrupt
bind
viral
glycoprotein
host
cell
receptor
addit
heavi
uniqu
glycosyl
pattern
found
viral
glycoprotein
provid
anoth
level
viru
specif
could
increas
select
virustarget
therapeut
prophylact
regard
use
carbohydratebind
protein
collect
call
lectin
explor
new
therapeut
antivir
strategi
recent
discov
virustarget
lectin
includ
banana
lectin
cyanovirin
microvirin
scytovirin
griffithsin
grft
among
grft
studi
extens
develop
either
antivir
therapeut
prevent
microbicid
due
extrem
potenc
low
vitro
vivo
host
toxic
favor
subclin
outcom
seriou
endeavor
develop
antivir
therapeut
vaccin
hiv
began
epidem
earli
hiv
infect
link
develop
acquir
immun
defici
syndrom
aid
effect
antivir
drug
avail
time
diagnosi
hiv
infect
death
sentenc
patient
howev
introduct
highli
activ
antiretrovir
therapi
haart
improv
patient
outcom
render
aid
clinic
manag
diseas
howev
lack
prevent
measur
hiv
vaccin
hinder
effort
decreas
number
new
hiv
case
per
year
particularli
young
women
live
resourcepoor
hivendem
region
subsaharan
africa
vulner
popul
new
hiv
infect
sinc
freedom
control
sexual
situat
use
protect
devic
individu
practic
unprotect
recept
anal
intercours
urai
also
respons
ongo
spread
new
hiv
infect
high
preponder
hiv
target
cell
traumat
rectal
mucos
area
therefor
two
hivvulner
popul
need
new
type
hiv
prevent
strategi
end
topic
antihiv
microbicid
cream
gel
intravagin
ring
could
promis
ondemand
preexposur
prophylact
option
vulner
popul
also
gener
public
grft
red
algaederiv
lectin
amino
acid
figur
exhibit
potent
picomolar
rang
broadspectrum
antivir
activ
neglig
vitro
vivo
host
toxic
antivir
activ
relat
uniqu
structur
featur
form
homodimer
complex
three
carbohydratebind
domain
monom
figur
three
carbohydratebind
domain
target
highmannos
array
present
mani
pathogen
envelop
virus
includ
hiv
sever
acut
middl
east
respiratori
syndrom
coronavirus
sarscov
merscov
hepat
c
viru
hcv
herp
simplex
viru
japanes
enceph
viru
jev
porcin
epidem
diarrhea
viru
pedv
result
broad
antivir
spectrum
show
great
promis
gener
microbicid
agent
prevent
viral
transmiss
therapeut
envelop
virusmedi
diseas
discoveri
clinic
develop
much
interest
surround
grft
potenti
first
clinic
proven
prevent
measur
variou
viral
diseas
review
structur
characterist
grft
examin
also
vitro
antivir
activ
hiv
studi
target
pathogen
grft
far
discuss
detail
use
varieti
combin
studi
result
involv
current
antiretrovir
drug
antivir
mechan
action
grft
explain
conjunct
viral
resist
profil
grft
addit
vitro
vivo
toxic
profil
summar
pharmacokinet
vivo
efficaci
studi
result
delin
provid
practic
drug
develop
perspect
largescal
product
formul
strategi
well
drug
deliveri
strategi
grft
hivprevent
biolog
discuss
final
ongo
clinic
studi
grft
effect
virus
hiv
summar
grft
carbohydratebind
protein
made
amino
acid
kda
size
uniqu
amino
acid
residu
posit
match
standard
amino
acid
figur
initi
isol
aqueou
extract
red
alga
griffithsia
sp
collect
water
shore
new
zealand
research
us
nation
cancer
institut
first
report
potent
cytoprotect
activ
tlymphoblastoid
cell
five
research
paper
report
structur
result
grft
use
either
xray
crystallographi
nuclear
magnet
reson
nmr
techniqu
tabl
term
structur
classif
grft
jacalinrel
lectin
harbor
three
repeat
antiparallel
fourstrand
triangular
prism
shape
figur
call
domainswap
dimer
two
one
protein
form
dimer
display
domainexchang
properti
two
counterpart
three
ident
carbohydratebind
site
locat
within
residu
monom
three
conserv
glycinerich
repeat
ggsgg
estim
mani
highmannos
oligosaccharid
present
one
protein
therefor
grft
multival
interact
via
three
carbohydratebind
domain
seem
essenti
highaffin
potenc
low
concentr
picomolar
rang
particular
three
aspart
residu
carbohydratebind
site
play
critic
role
interact
grft
highmannos
type
oligosaccharid
compos
nine
mannos
molecul
two
nacetyl
glucosamin
support
studi
demonstr
grft
point
mutat
partial
inhibit
abil
bind
grft
mutant
three
mutat
lose
almost
bind
capac
addit
tyrosin
residu
necessari
grft
bind
carbohydr
howev
appar
dispar
abil
inhibitori
potenc
grft
variant
indic
exist
anoth
antivir
mechan
beyond
simpl
bind
regard
carbohydratebind
specif
six
grft
dimer
carbohydratebind
site
occupi
mannos
glucos
nacetyl
glucosamin
similar
affin
determin
whether
grft
must
form
dimer
exert
antivir
activ
monomer
form
grft
mgrft
creat
insert
either
two
four
amino
acid
dimer
interfac
mgrft
possess
greatli
reduc
antivir
activ
spite
compar
associ
highmannos
oligosaccharid
sinc
mgrft
possess
three
carbohydratebind
site
suggest
intact
dimer
form
grft
requir
effici
disrupt
infect
sever
studi
describ
vitro
antihiv
activ
cytotox
grft
tabl
mori
et
al
report
potent
subnanomolar
antivir
efficaci
nativ
recombin
grft
laboratori
strain
primari
isol
tropic
public
observ
grft
inhibit
solubl
bind
receptorexpress
cell
celltocel
fusion
transmiss
infect
also
block
grft
similar
concentr
addit
coadministr
monosaccharid
glucos
mannos
nacetyl
glucosamin
hinder
glycosylationdepend
bind
grft
solubl
parallel
observ
emau
et
al
also
demonstr
grft
could
block
infect
hiv
virus
picomolar
concentr
also
confirm
longterm
stabil
grft
cervicalvagin
lavag
order
har
hivinactiv
power
grft
new
peptid
call
design
base
three
carbohydratebind
amino
acid
sequenc
grft
submicromolar
antihiv
activ
confirm
use
vitro
tzmbl
cell
line
gag
antigen
releas
assay
addit
abil
suppress
transmiss
tlymphocyt
grft
also
subvert
dcsign
dendrit
cellspecif
intercellular
adhes
nonintegrin
mediat
hiv
captur
mechanist
bind
competit
grft
dcsign
propos
potenti
mode
action
grftmediat
inhibit
captur
dcsign
correspond
dcsigndepend
antivir
activ
grft
also
potent
inhibit
giant
cell
format
persist
hivinfect
cell
noninfect
target
cell
led
suppress
hiv
transmiss
tcell
destruct
ultim
viral
replic
dcsign
mediat
pathway
effici
blockag
bind
dcsign
immobil
grft
confirm
observ
harmoni
grftmediat
expuls
complex
interestingli
highli
potent
inhibit
dcsignmedi
captur
transmiss
grft
markedli
impair
grft
mutat
one
three
carbohydratebind
site
implic
carbohydratebind
site
critic
determin
activ
regard
cytotox
two
studi
demonstr
concentr
grft
sever
hundr
nanomolar
thousand
time
higher
report
antivir
concentr
four
studi
describ
combin
effect
grft
either
current
antihiv
drug
potenti
therapeut
develop
tabl
grft
show
synergist
antivir
activ
tenofovir
maraviroc
antagonist
enfuvirtid
fusion
peptid
inhibitor
differ
glycosyl
pattern
viral
envelop
clade
b
clade
c
observ
effect
synergist
antivir
action
coval
link
grft
peptid
also
exhibit
potenc
severalfold
greater
grft
alon
inhibit
hiv
envmedi
fusion
cellcel
fusion
assay
line
observ
grftantiretrovir
drug
entri
inhibitor
revers
transcriptas
inhibitor
integras
inhibitor
proteas
inhibitor
combin
display
either
synergist
addit
effect
inhibit
fusion
protect
target
cell
destruct
grftantiretrovir
combin
also
potent
inhibit
shortterm
viral
replic
tcell
via
dcsignmedi
transmiss
combin
grft
carbohydratebind
agent
cba
includ
hippeastrum
hybrid
agglutinin
galanthu
nivali
agglutinin
mannosespecif
monoclon
antibodi
mab
microvirin
banana
lectin
also
show
synergist
activ
even
certain
cbaresist
strain
none
cba
compet
glycanbind
site
sinc
distinct
bind
pattern
envelop
addit
antivir
synergi
complex
show
higher
immunogen
individu
protein
per
se
suggest
remov
mannos
moieti
monomer
improv
humor
immun
respons
protein
six
differ
antivir
mechan
action
grft
propos
tabl
carbohydr
bindingdepend
antivir
mechan
grft
explor
use
hivspecif
neutral
monoclon
antibodi
mab
grft
preferenti
inhibit
bind
mab
target
nlink
glycan
posit
suggest
overlap
bind
specif
mab
addit
grft
increas
interact
mab
recogn
epitop
grft
also
enhanc
bind
plate
coat
mab
indic
bind
grft
trigger
exposur
site
particular
glycan
posit
shield
bind
domain
also
involv
grftmediat
bind
enhanc
neutral
synergi
grft
addit
synergi
grft
also
exhibit
isol
becam
sensit
neutral
upon
increas
bind
grft
mab
togeth
data
suggest
grftmediat
blockag
receptor
bind
event
coreceptor
bind
might
anoth
plausibl
mechan
grft
inhibit
infect
sinc
glycan
play
import
role
shield
neutralizationsensit
epitop
antibodi
recognit
disrupt
mannos
molecul
grft
may
also
increas
antibodydepend
neutral
particl
although
multival
interact
grft
highmannos
oligosaccharid
believ
account
picomolar
antivir
potenc
looser
correl
abil
hiv
inhibitori
potenc
bind
site
mutant
grft
suggest
possibl
anoth
unknown
antivir
mechan
grft
base
simpl
bind
accord
isotherm
titrat
calorimetri
bind
studi
grft
bound
glucos
nacetyl
glucosamin
similar
fashion
mannos
demonstr
flexibl
specif
bind
carbohydr
bind
flexibl
might
implic
broad
antivir
spectrum
studi
potenti
role
grft
dimer
suppress
infect
either
two
four
amino
acid
insert
dimer
interfac
grft
result
monomer
form
grft
mgrft
greatli
reduc
antivir
activ
result
emphas
import
multival
interact
dimer
grft
oligosaccharid
present
hiv
envelop
glycoprotein
success
crosslink
aggreg
viral
particl
interestingli
oblig
dimer
grft
peptid
linker
two
subunit
alter
structur
expos
bind
site
howev
grftlinkergrft
mutat
carbohydratebind
site
larg
lost
abil
hand
glycanspecif
dcsign
receptor
bind
viru
mediat
transfer
cell
regard
grft
abil
partial
block
bind
human
dcsign
potent
inhibit
dcsigndepend
transfer
could
synerg
antivir
action
block
viral
entri
maxim
antivir
synergi
caus
grft
multimer
tandem
repeat
mgrft
mgrft
tandem
engin
display
picomolarlevel
antivir
activ
wholecel
antihiv
assay
howev
sinc
mgrft
tandem
could
aggreg
hiv
virion
moulaei
et
al
suggest
intravirion
crosslink
hiv
envelop
glycoprotein
may
integr
antivir
activ
intervirion
aggreg
cluster
viral
membran
found
relat
neutral
potenc
five
studi
character
viral
resist
profil
caus
chronic
grft
treatment
tabl
sinc
antivir
activ
grft
mainli
depend
disrupt
biolog
function
multipl
mannos
molecul
viral
glycoprotein
reduct
glycosyl
level
target
protein
lead
grft
resist
exampl
glycosyl
site
involv
grftinduc
neutral
sinc
concomit
lack
glycan
posit
result
natur
grft
resist
convers
introduc
glycosyl
site
clade
c
viru
increas
grft
antivir
potenc
line
observ
deglycosyl
posit
decreas
sensit
singl
transmitterfound
hiv
env
grft
sinc
grftspecif
highmannos
nlink
glycosyl
site
singl
deglycosyl
primari
tcelllineadapt
isol
also
result
mark
resist
grft
furthermor
glycosyl
site
posit
locat
region
region
also
implic
grft
resist
loss
glycosyl
site
well
rearrang
glycan
also
led
subtyp
c
resist
grft
case
dcsigndepend
antivir
activ
grft
effect
extra
glycosyl
seem
depend
locat
glycosyl
exampl
introduct
glycosyl
site
abolish
sensit
lectin
abil
inhibit
bind
dcsign
viru
transfer
howev
addit
glycosyl
site
enhanc
inhibit
dcsigndepend
transfer
grft
given
overlap
natur
bind
specif
display
grft
neutral
antibodi
grft
resist
could
also
affect
sensit
antibodydepend
neutral
ubiquit
natur
glycosyl
protein
bodi
rais
concern
grft
may
caus
toxic
interact
glycosyl
host
protein
reason
effect
grft
host
cell
anim
studi
extens
accord
five
previou
report
grft
exhibit
toxic
activ
antivir
concentr
tabl
grft
induc
minim
chang
secret
inflammatori
cytokin
chemokin
epitheli
cell
human
peripher
blood
mononuclear
cell
pbmc
addit
measur
effect
cell
viabil
level
tcell
activ
marker
grft
treatment
induc
minim
alter
gene
express
profil
human
ectocerv
cell
also
caus
signific
cell
death
mitogen
activ
cytokin
releas
mous
pbmc
obviou
chang
observ
anim
fit
blood
chemistri
complet
blood
count
paramet
grfttreat
mice
interestingli
pbmcbound
form
grft
still
abl
maintain
antivir
activ
rais
potenti
versatil
vivo
antivir
activ
chronic
intravagin
system
administr
mgkg
grft
also
nontox
mice
grft
administ
gel
form
associ
chang
rectal
proteom
increas
abund
two
common
benefici
microbi
taxa
grft
treatment
due
placebo
formul
grft
associ
placebo
gel
chang
rectal
proteom
microbiota
indic
need
alter
compon
placebo
gel
futur
studi
grft
also
well
toler
subcutan
administr
guinea
pig
mous
model
addit
grft
found
nonirrit
noninflammatori
human
cervic
explant
vivo
rabbit
vagin
irrit
model
studi
mitogen
activ
report
cultur
human
lymphocyt
treat
grft
howev
follow
grft
treatment
revers
splenomegali
observ
activ
certain
spleen
b
cell
grftassoci
increas
spleen
liver
mass
also
note
anoth
studi
therefor
immun
respons
elicit
grft
treatment
control
order
avoid
potenti
grft
immunerel
toxic
three
studi
conduct
examin
vivo
antivir
efficaci
pharmacokinet
behavior
grft
use
variou
small
anim
model
tabl
subcutan
inject
grft
guinea
pig
mice
well
toler
result
accumul
grft
relev
therapeut
concentr
serum
grfttreat
anim
found
retain
antivir
activ
pseudovirus
cellbas
neutral
assay
addit
activ
grft
capabl
neutral
hivenv
pseudovirus
also
detect
rat
fecal
extract
chronic
oral
dose
vivo
efficaci
grft
also
demonstr
human
bone
marrowliverthymu
mice
protect
vagin
infect
treat
recombin
c
crescentu
express
grft
howev
grft
oral
bioavail
even
chronic
treatment
clinic
applic
protein
drug
requir
costeffect
largescal
product
procedur
meet
high
volum
need
clinic
set
effici
grft
product
seven
differ
product
method
develop
optim
tabl
giomarelli
et
al
use
ferment
rich
autoinduc
medium
led
approxim
increas
total
amount
grft
per
liter
approxim
protein
express
solubl
fraction
keef
et
al
abl
produc
grft
multigram
quantiti
use
nicotiana
benthamiana
plant
transduc
tobacco
mosaic
viru
vector
express
grft
hahn
et
al
employ
simpl
spray
method
introduc
agrobacterium
vector
nicotiana
plant
presenc
surfact
substitut
vacuum
inocul
found
recombin
grft
stabl
storag
plant
biomass
silag
suitabl
mass
product
costsensit
product
fuqua
et
al
howev
develop
simplifi
grft
purif
method
achiev
pure
grft
gener
initi
green
juic
extract
ph
buffer
heat
extract
incub
overnight
bentonit
mixtur
purifi
via
chromatographi
vamvaka
et
al
success
produc
grft
use
endosperm
transgen
rice
plant
oryza
sativa
found
crude
pure
grft
potent
antihiv
activ
crude
extract
toxic
human
cell
line
suggest
crude
grft
minim
process
could
administ
reduc
cost
associ
purif
petrova
et
al
express
grft
probiot
strain
lactobacillu
rhamnosu
gg
l
rhamnosu
gastrointestin
vagin
mucos
deliveri
respect
hoelscher
et
al
use
stabli
transform
tobacco
chloroplast
produc
grft
account
total
solubl
protein
plant
also
found
tobacco
dri
provid
storabl
sourc
grft
purifi
later
date
howev
produc
nicotiana
benthamiana
kim
et
al
found
grft
patholog
effect
plant
direct
apoplast
product
result
necrot
symptom
associ
hypersensit
respons
hr
like
cell
death
found
specif
interact
grft
apoplastloc
endogen
glycoprotein
initi
hr
respons
suppress
grftinduc
cell
death
nicotiana
benthamiana
exogen
express
naphthalen
hydroxylas
suggest
author
avoid
emerg
strain
resist
singl
microbicid
vamvaka
et
al
express
compon
multipl
antihiv
protein
includ
grft
mab
cyanovirinn
rice
endosperm
found
extract
plant
express
three
protein
show
enhanc
vitro
bind
synergist
neutral
unexpectedli
also
found
synergist
hiv
neutral
caus
tripl
microbicid
enhanc
product
rice
endosperm
rice
globulin
protein
enhanc
bind
express
protein
protein
stabil
critic
longterm
mainten
pharmacolog
activ
reason
suscept
grft
proteolyt
digest
consid
grft
resist
digest
eight
differ
proteas
includ
pepsin
papain
leucin
aminopeptidas
pronas
proteinas
k
endoproteinas
trypsin
number
differ
nanoparticl
drug
deliveri
system
test
provid
sustain
control
deliveri
grft
improv
solubl
protect
payload
enhanc
mucos
permeabl
tabl
plga
poli
lacticcoglycol
acid
nanoparticl
diamet
approxim
nm
success
use
codeliveri
grft
dapivirin
vitro
drug
show
biphas
releas
initi
burst
phase
follow
sustain
releas
phase
groom
et
al
success
gener
grftmodifi
electrospun
fiber
inactiv
hiv
prior
cellular
entri
furthermor
lal
et
al
develop
selfadminist
vagin
fastdissolv
insert
fdi
produc
freezedri
deliv
safe
effect
amount
grft
carrageenan
gc
sulfat
polysaccharid
extract
seawe
fiber
compris
methoxi
polyethylen
glycolplga
poli
nbutyl
acrylatecoacryl
acid
mpegplga
pbacopaa
abl
achiev
high
grft
load
grftload
fiber
well
maintain
within
simul
vagin
fluid
svf
show
phdepend
releas
upon
exposur
buffer
svf
simul
semen
solut
date
two
phaseon
clinic
studi
initi
investig
potenti
toxic
grft
healthi
popul
first
studi
aim
evalu
safeti
grft
cg
gel
use
vagin
singl
dose
consecut
day
healthi
women
twopart
studi
first
part
consist
singledos
openlabel
design
second
part
consist
multipledos
random
placebocontrol
studi
design
second
part
subject
administ
placebo
subject
given
grft
gel
studi
pharmacokinet
behavior
grft
also
analyz
form
timeconcentr
curv
grft
blood
sampl
howev
rise
dose
toler
studi
minim
system
absorb
grft
report
preclin
studi
although
offici
studi
result
avail
yet
popul
council
websit
report
grft
safe
vagin
use
day
potent
antihiv
activ
cellbas
assay
cervic
explant
h
receiv
dose
anoth
phaseon
clinic
studi
grft
start
integr
preclinicalclin
program
program
name
prevent
preexposur
prevent
viral
entri
aim
provid
comprehens
set
data
facilit
inform
decis
whether
grft
progress
within
topic
microbicid
pipelin
random
doubleblind
phaseon
safeti
pharmacokinet
studi
grft
enema
administ
rectal
seroneg
adult
practic
urai
number
frequenc
advers
event
blood
concentr
grft
chang
humor
antibodi
respons
analyz
ongo
clinic
studi
complet
grft
display
antivir
activ
hiv
also
envelop
virus
sarscov
merscov
hcv
hsv
jev
pedv
even
human
papillomaviru
hpv
nonenvelop
viru
inactiv
grft
via
glycosylationindepend
mechan
grft
specif
bound
sarscov
spike
glycoprotein
inhibit
viral
entri
grft
also
inhibit
particl
pseudotyp
merscov
spike
protein
enter
host
cell
preincub
hcv
particl
grft
prevent
infect
hepatoma
cell
furthermor
grft
abl
interfer
direct
celltocel
transmiss
hcv
antihcv
activ
demonstr
vivo
hcv
infect
mitig
chimer
mice
report
grft
readili
bioavail
subcutan
inject
show
signific
vivo
efficaci
reduc
hcv
viral
titer
mous
model
system
engraft
human
hepatocyt
contrast
hiv
hcv
resist
grft
directli
confer
mutat
envelop
protein
gene
could
occur
indirect
mechan
involv
mutat
viral
protein
grft
display
modest
inhibitori
activ
present
viral
entri
present
postentri
complet
block
plaqu
format
reduc
plaqu
size
prevent
celltocel
propag
vitro
find
translat
signific
protect
genit
herp
mice
treat
griffithsin
gel
vivo
antihsv
activ
grft
demonstr
murin
model
test
subject
protect
c
crescentu
express
grft
intravagin
infect
levendoski
et
al
explor
antivir
properti
combin
product
compos
grft
cg
hpv
found
grft
abl
block
entri
hpv
target
cell
adsorpt
hpv
onto
target
cell
grftcg
combin
also
test
freezedri
fdi
formul
product
protect
rhesu
macaqu
highdos
vagin
simian
hiv
challeng
h
fdi
insert
furthermor
grftcg
fdi
also
protect
mice
vagin
hpv
pseudoviru
vitro
experi
show
treatment
jev
grft
inocul
bhk
cell
inhibit
infect
dosedepend
manner
vivo
experi
show
grft
mgkg
administ
intraperiton
viru
infect
prevent
mortal
mice
challeng
intraperiton
lethal
dose
jev
regard
antivir
mechan
grft
shown
bind
jev
glycosyl
viral
protein
specif
envelop
prematur
glycoprotein
addit
grft
abl
reduc
pedv
infect
vero
cell
due
novel
carbohydratetarget
antivir
mechan
action
superior
efficaci
excel
host
toxic
profil
synergist
interact
antiretrovir
drug
optim
largescal
product
methodolog
variou
formul
method
effici
deliveri
grft
hold
great
promis
first
topic
proteinbas
antihiv
preexposur
prophylact
even
though
potenti
advers
immunotox
issu
observ
preclin
anim
studi
need
resolv
broad
antivir
spectrum
applic
envelop
virus
could
make
grft
first
univers
antivir
therapeut
specif
target
viru
carbohydr
favor
outcom
two
ongo
phaseon
clinic
trial
acceler
drug
develop
process
approv
grft
provid
superior
way
prevent
mani
transmiss
viral
infect
